DOCSLIB.ORG

To USP 39–NF 34, Second Supplement the Following Index Is

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
To USP 39–NF 34, Second Supplement the Following Index Is Index to USP 39–NF 34, Second Supplement The following Index is for convenience and informational use only and shall not be used for interpretive purposes. In addition to official articles, this Index may also include items recently omitted from the USP–NF in the indicated Book or Supplement. The requirements stated in the General Notices and Requirements section of the USP–NF apply to all articles recognized in the USP–NF and to all general chapters unless specifically stated otherwise. Although this revision (USP 39–NF 34 2S) is generally official beginning December 1, 2016; particular provisions may indicate another earlier or later official date. In addition, the monographs and general chapters listed in this Index may reference other general chapter specifications. The articles listed in this Index are not intended to be autonomous standards and should only be interpreted in the context of the entire USP–NF publication. For the most current version of the USP–NF please see the USP–NF Online Combined Index to USP 39 and NF 34 Abaca-Acety I-1 Combined Index to USP 39 and NF 34, including Second Supplement Page citations refer to the pages of Volumes 1, 2, 3, and 4 of USP 39±NF 34 and its First and Second Supplement. This index is repeated in its entirety in each volume. 1±2280 Volume 1 2281±4454 Volume 2 4455±6446 Volume 3 6447±7608 Volume 4 7609±8194 First Supplement 8195±8863 Second Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, extended-release tablets, 2300 A dextromethorphan, and and tramadol hydrochloride oral pseudoephedrine, oral powder suspension, 6214, 8851 Abacavir containing at least three of the and tramadol hydrochloride tablets, 2323 oral solution, 2281 following, 2306 Acetanilide, 2084 sulfate, 2283 and (salts of) chlorpheniramine, Acetate tablets, 2282 dextromethorphan, and methyl, 2126 and lamivudine tablets, 7977 pseudoephedrine, oral solution Acetate buffer, 2166 Abiraterone containing at least three of the TS, 2167 acetate, 2285 following, 2308 Acetazolamide, 2325, 7980 acetate tablets, 2286 and (salts of) chlorpheniramine, for injection, 2325, 7981 Absolute dextromethorphan, and oral suspension, 2326, 8572 alcohol, 2085 pseudoephedrine, tablets containing at tablets, 2327, 7982 ether, 2084 least three of the following, 2310 Acetic acid, 2084, 7139 Absorbable chlorpheniramine maleate, and ammonium acetate buffer TS, 2167 dusting powder, 3640 dextromethorphan hydrobromide diluted, 2084, 7139 gelatin film, 4096 tablets, 2312 double-normal (2 N), 2177 gelatin sponge, 4096 and codeine phosphate capsules, 2314 glacial, 2084, 2327 surgical suture, 5978 and codeine phosphate oral solution, 2315 glacial, TS, 2167 Absorbent and codeine phosphate oral suspension, and hydrocortisone otic solution, 4223 cotton, 2084 2316 irrigation, 2328 gauze, 4094 and codeine phosphate tablets, 2317 metaphosphoric, TS, 2172 odorless paper, 2131 dextromethorphan hydrobromide, otic solution, 2328 Acacia, 7137 doxylamine succinate, and strong, TS, 2167 syrup, 7137 pseudoephedrine hydrochloride oral Acetic acid in peptides, 357 Acarbose, 2288 solution, 2318 Acetic anhydride, 2084 Acebutolol hydrochloride, 2289 and diphenhydramine citrate tablets, 2319 Acetohexamide, 2329 capsules, 2291 diphenhydramine hydrochloride, and tablets, 2329 Acepromazine maleate, 2292 pseudoephedrine hydrochloride tablets, Acetohydroxamic acid, 2329 injection, 2293 2320 tablets, 2330 tablets, 2293 and hydrocodone bitartrate tablets, 4214 Acetone, 2084, 7140 Acesulfame potassium, 7138 isometheptene mucate, and anhydrous, 2084 Acetal, 2084 dichloralphenazone capsules, 4407 neutralized, 2084, 2167 Acetaldehyde, 2084 and oxycodone capsules, 5225 Acetonitrile, 2084 TS, 2167 and oxycodone tablets, 5227 spectrophotometric, 2084 Acetaminophen, 2294 and pentazocine tablets, 5326 Acetophenone, 2084 aspirin and caffeine tablets, 2302 and propoxyphene hydrochloride tablets, p-Acetotoluidide, 2084 and aspirin tablets, 2301 5582 Acetylacetone, 2084 butalbital and caffeine capsules, 2827 and propoxyphene napsylate tablets, 5587 Acetyl chloride, 2084 butalbital and caffeine tablets, 2828 and pseudoephedrine hydrochloride Acetylcholine chloride, 2084, 2331 and caffeine tablets, 2303, 7979 tablets, 2322 for ophthalmic solution, 2332 capsules, 2296 oral solution, 2296 and (salts of) chlorpheniramine, for effervescent oral solution, 2297 dextromethorphan, and suppositories, 2298, 8571 pseudoephedrine, capsules containing at oral suspension, 2298 least three of the following, 2304 tablets, 2299 I-2 Acety-Alumi Combined Index to USP 39 and NF 34 Acetylcysteine, 2333 Inhalation and nasal drug products: Aldehyde dehydrogenase, 2086 and isoproterenol hydrochloride inhalation aerosols, sprays, and powdersÐ Alendronate sodium, 2367, 7984 solution, 2334 performance quality tests 〈601〉, 423 tablets, 2368 solution, 2334 Isoetharine mesylate inhalation, 4401 Alfadex, 7147 N-Acetylglucosamine, 6447 Isoproterenol hydrochloride inhalation, Alfentanil 3-Acetylthio-2-methylpropanoic acid, 2085 4415 hydrochloride, 2370 Acetyltributyl citrate, 7141 Isoproterenol hydrochloride and injection, 2370 Acetyltriethyl citrate, 7141 phenylephrine bitartrate inhalation, 4417 Alfuzosin hydrochloride, 2371 N-Acetyltyrosine, 6448 Isoproterenol sulfate inhalation, 4420 extended-release tablets, 2372 N-Acetyl-L-tyrosine ethyl ester, 2085 Lidocaine topical, 4560 Alginates assay 〈311〉, 288 Acid Metaproterenol sulfate inhalation, 4757 Alginic acid, 7148 acrylic, 2085 Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 2086 alpha lipoic, 6731 topical, 5446 Alkaline dehydroacetic, 7272 Povidone±iodine topical, 5483 borate buffer, 2166 ferric chloride TS, 2167 Terbutaline sulfate inhalation, 6055 cupric citrate TS, 2167 ferrous sulfate TS, 2167 Thimerosal topical, 6116 cupric citrate TS 2, 2167 iminodiacetic, 2121 Tolnaftate topical, 6194 cupric iodide TS, 2167 phthalate buffer, 2165 Triamcinolone acetonide topical, 6237 cupric tartrate TS, 2167 stannous chloride TS, 2167 mercuric-potassium iodide TS, 2167 stannous chloride TS, stronger, 2167 phosphatase enzyme, 2086 Acid-neutralizing capacity 〈301〉, 287 picrate TS, 2167 Acidulated phosphate and sodium fluoride Agar, 2085, 7143 pyrogallol TS, 2174 topical solution, 5874 Agarose, 2085 sodium hydrosulfite TS, 2167 Acitretin, 2335 Air, medical, 2348 Alkyl (C12-15) benzoate, 7149 capsules, 2336 Air-helium certified standard, 2085 Alkylphenoxypolyethoxyethanol, 2086 Acoustic emission 〈1005〉, 763 Alanine, 2349 Allantoin, 2377 Acrylic acid, 2085 L-Alanyl-L-glutamine, 6450 Allopurinol, 2378 Activated Albendazole, 2350 oral suspension, 2380, 8572 alumina, 2085 oral suspension, 2351 tablets, 2380 charcoal, 2085, 3080 tablets, 2351 Allyl isothiocyanate, 2381 magnesium silicate, 2085 Albumen TS, 2167 Almond oil, 7149 Acyclovir, 2338 Albumin Almotriptan capsules, 2339 bovine serum, 2085 tablets, 2384 for injection, 2340 human, 2352 Almotriptan malate, 2381 ointment, 2341 rAlbumin human, 7144 Aloe, 2385 oral suspension, 2342 Albuterol, 2353 Alpha tablets, 2342 sulfate, 2357 lipoic acid, 6731 Adamantane, 2085 tablets, 2353 Alpha-chymotrypsin, 2086 Adapalene, 2343 extended-release tablets, 2354 Alpha cyclodextrin hydrate, 2086 gel, 7983 Alclometasone dipropionate, 2358 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Ademetionine disulfate tosylate, 6449 cream, 2359 2086 Adenine, 2346 ointment, 2360 Alphanaphthol, 2086 sulfate, 2085 Alcohol, 2085, 2361 Alphazurine 2G, 2162 Adenosine, 2347 70 percent, 80 percent, and 90 percent, Alprazolam, 2386 injection, 2348 2085 oral suspension, 2387, 8573 Adipic acid, 2085, 7142 absolute, 2085 tablets, 2388 Admissions aldehyde-free, 2085 extended-release tablets, 2389, 7986 to NF 34, 7125 alpha-(2-(methylamino)ethyl)benzyl, 2086 orally disintegrating tablets, 2393 to USP 39, xxxv amyl, 2085 Alprenolol hydrochloride, 2086 Adulteration of dietary supplements with tert-amyl, 2089 Alprostadil, 2395 drugs and drug analogs 〈2251〉, 7821 butyl, 7186 injection, 2397 Advisory Groups, xx, 7621, 8207 dehydrated, 2085, 2363 Alteplase, 2398 dehydrated isopropyl, 2085 for injection, 2401 denaturated, 2085 Alternative microbiological sampling methods denaturated, TS, 2170 for nonsterile inhaled and nasal products determination 〈611〉, 454 〈610〉, 452 Aerosol in dextrose injection, 2365 Altretamine, 2403 Bacitracin and polymyxin B sulfate topical, diluted, 2086, 7146 capsules, 2404 2673 injection, dehydrated, 2364 Alum, 2086 Benzocaine, butamben, and tetracaine isobutyl, 2086 ammonium, 2086, 2405 hydrochloride topical, 2713 isopropyl, 2086 potassium, 2137, 2405 Benzocaine and menthol topical, 2716 methyl, 2086 Alumina, 2086 Benzocaine topical, 2704 neutralized, 2086 activated, 2086 Betamethasone dipropionate topical, 2740 phenol TS, 2167 anhydrous, 2086 Dexamethasone sodium phosphate n-propyl, 2086 aspirin, codeine phosphate, and magnesia inhalation, 3407 rubbing, 2366 tablets, 2616 Dexamethasone topical, 3398 secondary butyl, 2086 aspirin, and magnesia tablets, 2610 Epinephrine bitartrate inhalation, 3715 tertiary butyl, 2086 aspirin, and magnesium oxide tablets, Epinephrine inhalation, 3712 Alcoholic 2611 Ergotamine tartrate inhalation, 3736 ammonia TS, 2167 magnesia, and calcium carbonate Fluticasone propionate inhalation, 4001 mercuric bromide TS, 2167 chewable tablets, 2409 Fluticasone propionate and salmeterol, potassium hydroxide TS, 2167 magnesia, calcium carbonate, and inhalation, 4015 potassium hydroxide TS 2, 2174 simethicone chewable tablets, 2410
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al
    US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Theranostics and Contrast Agents for Magnetic Resonance Imaging Yohan Jeong, Hee Sook Hwang and Kun Na*
    Jeong et al. Biomaterials Research (2018) 22:20 https://doi.org/10.1186/s40824-018-0130-1 REVIEW Open Access Theranostics and contrast agents for magnetic resonance imaging Yohan Jeong, Hee Sook Hwang and Kun Na* Abstract Background: Magnetic resonance imaging is one of the diagnostic tools that uses magnetic particles as contrast agents. It is noninvasive methodology which provides excellent spatial resolution. Although magnetic resonance imaging offers great temporal and spatial resolution and rapid in vivo images acquisition, it is less sensitive than other methodologies for small tissue lesions, molecular activity or cellular activities. Thus, there is a desire to develop contrast agents with higher efficiency. Contrast agents are known to shorten both T1 and T2. Gadolinium based contrast agents are examples of T1 agents and iron oxide contrast agents are examples of T2 agents. In order to develop high relaxivity agents, gadolinium or iron oxide-based contrast agents can be synthesized via conjugation with targeting ligands or functional moiety for specific interaction and achieve accumulation of contrast agents at disease sites. Main body: This review discusses the principles of magnetic resonance imaging and recent efforts focused on specificity of contrast agents on specific organs such as liver, blood, lymph nodes, atherosclerotic plaque, and tumor. Furthermore, we will discuss the combination of theranostic such as contrast agent and drug, contrast agent and thermal therapy, contrast agent and photodynamic therapy, and neutron capture therapy, which can provide for cancer diagnosis and therapeutics. Conclusion: These applications of magnetic resonance contrast agents demonstrate the usefulness of theranostic agents for diagnosis and treatment.
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Vaginal Delivery System
    (19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Harmonised Bds Suppl 20070
    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
    [Show full text]
  • Substrate Inhibition of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 in Living Cells and Regulation Among the Steroid-Converting Enzymes in Breast Cancers
    Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Doctorat en médecine moléculaire Philosophiæ doctor (Ph. D.) Québec, Canada © Hui Han, 2018 Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Sous la direction de : Sheng-xiang Lin, directeur de recherche RÉSUMÉ Cette étude a permis de démontrer les fonctions et les mécanismes de la 17bêta- hydroxystéroïde déshydrogénase de type 1 (17β-HSD1) et de la stéroïde sulfatase (STS) au niveau du cancer du sein, y compris la cinétique moléculaire et cellulaire, la liaison du ligand étudiée par la titration de fluorescence, la régulation des stéroïdes et la régulation mutuelle entre les enzymes stéroïdiennes et les cellules cancéreuses du sein. 1), L’inhibition de la 17β-HSD1 par son substrat a été démontrée par la cinétique enzymatique au niveau cellulaire pour la première fois, soutenant ainsi la fonction biologique de l’inhibition produite par le substrat. 2), En tant qu’inhibiteur, la dihydrotestostérone (DHT) n’a pas affecté la concentration du substrat estrone (E1) à laquelle l’activité enzymatique a commencé à diminuer, mais certaines augmentations de vitesse ont été observées, suggérant une diminution significative de l’inhibition par le substrat. 3), Les résultats de la modulation de l’ARNm ont démontré que la transcription du gène codant la 17β-HSD7 diminuait en réponse à l’inhibition de la 17β-HSD1 ou au knockdown dans les cellules du cancer du sein par la modification estradiol (E2).
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET Preparation Date: 07/06/2015 Revision Date: 12/28/2017 Revision Number: G2 1. IDENTIFICATION Product identifier Product code: C2322 Product Name: CYANOACETIC ACID Other means of identification Synonyms: Acide cyanacetique [French] Cyanessigsaeure [German] Kyselina kyanoctova [Czech] Malonic acid mononitrile Malonic mononitrile Monocyanoacetic acid Acetic acid, 2-cyano- Acetic acid, cyano- CAS #: 372-09-8 RTECS # AG3675000 CI#: Not available Recommended use of the chemical and restrictions on use Recommended use: Chemical intermediate for malonic acid; diethyl malonate for pharmaceuticals; For the production of the fungicide cymoxanil and the cough remedy dextromethorphan. Uses advised against No information available Supplier: Spectrum Chemical Mfg. Corp 14422 South San Pedro St. Gardena, CA 90248 (310) 516-8000 Order Online At: https://www.spectrumchemical.com Emergency telephone number Chemtrec 1-800-424-9300 Contact Person: Martin LaBenz (West Coast) Contact Person: Ibad Tirmiz (East Coast) 2. HAZARDS IDENTIFICATION Classification This chemical is considered hazardous according to the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Considered a dangerous substance or mixture according to the Globally Harmonized System (GHS) Acute toxicity - Oral Category 4 Skin corrosion/irritation Category 1 Serious eye damage/eye irritation Category 1 Specific target organ toxicity (single exposure) Category 3 Label elements Product code: C2322 Product name: CYANOACETIC ACID 1 / 12 Danger Hazard statements Causes severe
    [Show full text]